Abstract Details

Title Effects of the CSF from Anti-NMDA Receptor Encephalitis Patient on the Cultured Neurons

Topic Neurotoxicology

Presentation(s) IN9 - (-)

Poster/Presentation
Number 002

Objective

Background Anti-NMDA receptor autoantibodies (NMDAR-Abs) are thought to relate closely to the pathogenesis of NMDAR encephalitis. The NMDARs have roles on memory, learning, or cognition and the patients with this disease frequently show impairment of these abilities as their major symptom. We had reported that the NMDAR-Ab-positive patient's CSF could reduce the size of long-term potentiation, a model for memory and learning, using mouse hippocampal slices. To understand the further pathomechanisms of this disease, we examined these antibody-effects on cultured neurons.

Design/Methods Primary culture of mouse hippocampal neurons were prepared and incubated with the patients' CSF or other controls with or without complement under incubation microscope to see their morphological changes chronologically. We also compared the mRNA expression in these neurons to see the background of the morphological changes.

Results The hippocampal neurons incubated with NMDAR-Ab-positive CSF showed that the neurons form thicker dendrites and connected with nearby neurons extensively than those incubated with antibody-absorbed patient's CSF or antibody-negative control CSF. A set of inflammation related molecules were overexpressed in these neurons.

Conclusions The CSF from the patients with NMDAR encephalitis effected as extension of neuronal outgrowth that might be related to the favorable long term outcome of this disease.

Authors/Disclosures
Keiko Tanaka, MD, PhD (Kanazawa Medical University) PRESENTER	Keiko Tanaka, MD, PhD has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Andrew E. Budson, MD (VA Boston Healthcare System)	Dr. Budson has received personal compensation for serving as an employee of Boston Center for Memory. Dr. Budson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Budson has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Eli Lilly. The institution of Dr. Budson has received research support from Department of Veterans Affairs. The institution of Dr. Budson has received research support from NIH. The institution of Dr. Budson has received research support from Bristol Myers Squibb. The institution of Dr. Budson has received research support from VoxNeuro. Dr. Budson has received publishing royalties from a publication relating to health care. Dr. Budson has received publishing royalties from a publication relating to health care. Dr. Budson has a non-compensated relationship as a Alzheimer's Advisory Panel with Commonwealth of Massachusetts that is relevant to AAN interests or activities.
Myassar Zarif	Myassar Zarif has nothing to disclose.
Makoto Matsui, MD, PhD, FAAN (Houju Memorial Hospital)	No disclosure on file
Masami Tanaka, MD, FAAN (Kyoto Min-iren Chuo Hosp)	Dr. Tanaka has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��